0000000000082721
AUTHOR
Jane Houldsworth
Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.
e16109Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease with progression as the best response. This s...
Novel chromosome copy number changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma
4552 Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease (PRD) with progression as the best response. T...